Cutting edge: The tumor counterattack hypothesis revisited: Colon cancer cells do not induce T cell apoptosis via the Fas (CD95, APO-1) pathway

Journal of Immunology

Volumn 164, Issue 10, 2000, Pages 5023-5027

  Favre Felix, Nathalie ^a   Fromentin, Annie ^a   Hammann, Arlette ^a   Solary, Eric ^a   Martin, François ^a   Bonnotte, Bernard ^a  

^a UNIVERSITÉ DE BOURGOGNE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

FAS ANTIGEN; TUMOR ANTIGEN;

ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; CANCER CELL; COLON CANCER; CONFOCAL MICROSCOPY; CONTROLLED STUDY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION;

EID: 0034657175     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.164.10.5023     Document Type: Article

References (26)

1. Nagata, S., and P. Golstein. 1995. The Fas death factor. Science 267:1449.
2. Dhein, J., H. Walczak, C. Baumler, K. M. Debatin, and P. H. Krammer. 1995. Autocrine T-cell suicide mediated by APO-1 (Fas/CD95). Nature 373:438.
3. Bellgrau, D., D. Gold, H. Selawry, J. Moore, A. Franzusoff, and R. C. Duke. 1995. A role for CD95 ligand in preventing graft rejection. Nature 377:630.
4. O'Connell, J., G. C. O'Sullivan, J. K. Collins, and F. Shanahan. 1996. The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand. J. Exp. Med. 184:1075.
5. Hahne, M., D. Rimoldi, M. Schröter, P. Romero, M. Schreier, L. E. French, P. Schneider, T. Bornand, A. Fontana, D. Lienard, et al. 1996. Melanoma cell expression of Fas (Apo-1/CD95) ligand: implications for tumor immune escape. Science 274:1363.
6. Saas, P, P. R. Walker, M. Hahne, A. L. Quiquerez, V. Schnuriger, G. Perrin, L. French, E. Van Meir, N. de Tribolet N. J. Tschopp, and P. Y. Dietrich. 1997. Fas ligand expression by astrocytoma in vivo: maintaining immune privilege in the brain? J. Clin. Invest. 99:1173.
7. Niehans, G. A., T. Brunner, S. P. Frizelle, J. C. Liston, C. T. Salerno, D. J. Knapp, D. R. Green, and R. A. Kratzke. 1997. Human lung carcinomas express Fas ligand. Cancer Res. 57:1007.
8. Shiraki, K., N. Tsuji, T. Shioda, K. J. Isselbacher, and H. Takahashi. 1997. Expression of Fas ligand in liver metastases of human colonic adenocarcinomas. Proc. Natl. Acad. Sci. USA 94:6420.
9. Rabinowich, H., T. E. Reichert, Y. Kashii, B. R. Gastman, M. C. Bell, and T. L. Whiteside. 1998. Lymphocyte apoptosis induced by Fas ligand-expressing ovarian carcinoma cells. Implications for altered expression of T cell receptor in tumor-associated lymphocytes. J. Clin. Invest. 101:2579.
10. Ungefroren, H., M. Voss, M. Jansen, C. Roeder, D. HenneBruns, B. Kremer, and H. Kalthoff. 1998. Human pancreatic adenocarcinomas express Fas and Fas ligand yet are resistant to Fas-mediated apoptosis. Cancer Res. 58:1741.
11. O'Connell, J., M. W. Bennett, G. C. O'Sullivan, J. K. Collins, and F. Shanahan. 1999. Fas counter-attack: the best form of tumor defense? Nat. Med. 5: 267.
12. Smith, D., S. Sieg, and D. Kaplan. 1998. Aberrant detection of cell surface Fas ligand with anti-peptide antibodies. J. Immunol. 160:4159.
13. Fiedler, P., C. E. Schaetzlein, and H. Eibel. 1998. Constitutive expression of FasL in thyrocytes. Science 279:2015a.
14. Böhm, C., M. L. Hanski, A. Gratchev, B. Mann, M. P. Moyer, E. O. Riecken, and C. A. Hanski. 1998. A modification of the JAM test is necessary for a correct determination of apoptosis induced by FasL' adherent tumor cells. J. Immunol. Methods 217:71.
15. Rensing-Ehl, A., K. Frei, B. Flury, B. Matiba, S.M. Mariani, M. Weller, P. Aebischer, P. H. Krammer, and A. Fontana. 1995. Local Fas/APO-1 (CD95) ligand-mediated tumor cell killing in vivo. Eur. J. Immunol. 25:2253.
16. Schneider, P., N. Holler, J. L. Bodmer, M. Hahne, K. Frei, A. Fontana, and J. Tschopp. 1998. Conversion of membrane-bound Fas(CD95) ligand to its soluble form is associated with downregulation of its proapoptotic activity and loss of liver toxicity. J. Exp. Med. 187:1205.
17. Bonnotte, B., N. Favre, S. Reveneau, O. Micheau, N. Droin, C. Garrido, A. Fontana, B. Chauffert, E. Solary, and F. Martin. 1998. Cancer cell sensitization to Fas-mediated apoptosis by sodium butyrate. Cell Death Differ. 5:480.
18. Matzinger, P. 1991. The JAM test: a simple assay for DNA fragmentation and cell death. J. Immunol. Methods 145:185.
19. Micheau, O., E. Solary, A. Hammann, F. Martin, and M. T. Dimanche-Boitrel. 1997. Sensitization of cancer cells treated with cytotoxic drugs to Fas-mediated cytotoxicity. J. Natl. Cancer Inst. 89:783.
20. Aragane, Y., D. Kulms, D. Metze, G. Wilkes, B. Pöppelmann, T. A. Luger, and T. Schwarz. 1998. Ultraviolet light induces apoptosis via direct activation of CD95 (Fas/APO-1) independently of its ligand CD95L. J. Cell Biol. 140:171.
21. Kayagaki, N., A. Kawasaki, T. Ebata, H. Ohmoto, S. Ikeda, S. Inoue, K. Yoshino, K. Okumura, and H. Yagita. 1995. Metalloproteinase-mediated release of human Fas ligand. J. Exp. Med. 182:1777.
22. Chappell, D. B., T. Z. Zaks, S. A. Rosenberg, and N. P. Restifo. 1999. Human melanoma cells do not express Fas (Apo-1/CD95) ligand. Cancer Res. 59:59.
23. Bossi, G., and G. M. Griffiths. 1999. Degranulation plays an essential part in regulating cell surface expression of Fas ligand in T cells and natural killer cells. Nat. Med. 5:90.
24. Allison, J., H. M. Georgiou, A. Strasser, and D. L. Vaux. 1997. Transgenic expression of CD95 ligand on islet beta cells induces a granulocytic infiltration but does not confer immune privilege upon islet allografts. Proc. Natl. Acad. Sci. USA 94:3943.
25. Kang, S. M., D. Le, M. L. Springer, P. G. Stock, and H. M. Blau. 1997. Immune response and myoblasts that express Fas ligand. Science 278:1322.
26. Zaks, T. Z., D. B. Chappell, S. A. Rosenberg, and N. P. Restifo. 1999. Fas-mediated suicide of tumor-reactive Tcells following activation by specific tumor: selective rescue by caspase inhibition. J. Immunol. 162:3273.